What's New in Research Funding

Page last updated June 22, 2018.

We are pleased to assist the research community in identifying potential sources of funding through the provision of information posted here:

  • All Applicants submitting through the University of Toronto MUST have submitted their application information online via the My Research Applications (MRA) portal. This is an online submission process to obtain institutional approval on research applications. Please note that you will be required to upload a copy of the application to this online submission. Please complete this step as early as possible and at least several days ahead of the deadline to insure all approvals are obtained on time. Please visit the OVPRI's MRA webpage for complete information on this process.
  • Please note, all grants requiring the Dean's signature should be brought to the Faculty of Medicine Research Office in the Medical Sciences Building, Room 2331 to the attention of Cindy Faber cindy.faber@utoronto.ca.
  • Also, our office offers a grant editing service for researchers submitting proposals to tri-council or any other funding agency. For more information, please contact dan.harney@utoronto.ca.
  • Recently received news and updates are posted below and sent via email to our LISTSERV. To join click here.

Comprehensive funding opportunities may be searched through these links:

Recently Received News and Updates:

Join in U of T’s advocacy efforts as we urge the federal government to implement all of the Fundamental Science Review Report’s recommendations. Get involved today and #supportthereport by phoning or writing your MP, sending a postcard to Ottawa, or making your support for research known on social media.

 

June 22, 2018
 

  • Minister of Health announces Dr. Michael J. Strong as new President of the CIHR (June 20, 2018). The Honourable Ginette Petitpas Taylor, Minister of Health, announced that Dr. Michael J. Strong has been appointed the new President of the Canadian Institutes of Health Research (CIHR). Dr. Strong is an internationally recognized researcher specializing in the neurodegenerative disease amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. He will take up his position on October 1. Dr. Strong’s research focuses on understanding the cellular biology of ALS. His work has helped shed new light on a process by which an abnormal form of some proteins may accumulate in nerve cells in the spinal cord and brain, destroying the cells, and leading to the symptoms of the disease. Dr. Strong will bring extensive leadership experience to CIHR, having served since 2010 as the Dean of the Schulich School of Medicine & Dentistry and Distinguished University Professor at Western University, where he holds the Arthur J. Hudson Chair in ALS Research. From 2000 to 2010, he served as the Chief of Neurology and Co-Chair of the Department of Clinical Neurological Sciences at the London Health Sciences Centre and Western University. Read the full new release.
     
  • Tri-Council Statement on Self-Identification Data Collection in Support of Equity, Diversity, and Inclusion. Government of Canada Open Letter to the Research Community. The Government of Canada is pleased to inform you that the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council (NSERC) and the Social Sciences and Humanities Research Council (SSHRC) will now ask all applicants to grant, scholarship, and fellowship programs to provide information on their age, gender, Indigenous identity, and/or status as a member of a visible minority group, and/or as a person with a disability.  Starting this summer, SSHRC and NSERC are asking all applicants for funding competitions (grants, scholarships, and fellowships) to self-identify with information on age, gender, Indigenous identity, and status as a member of a visible minority group or person with a disability. CIHR has also recently implemented this requirement. Read more. Further information on the Self-Identification Data can be found here.

     
  • CIHR/SSHRC/the International Development Research Centre (IDRC): Call for Proposals - Rapid Research Fund for Ebola Virus Disease Outbreaks.  The Call aims to support social science and humanities, population and public health and/or health systems research to increase collaboration and adaptive scaling of past evidence-based interventions that have proven successful in curbing Ebola Virus Disease transmission, promote novel approaches to remaining challenges, and link existing resources and expertise across the globe to inform the response to the outbreak of Ebola Virus Disease that started in April 2018 in the Democratic Republic of the Congo (DRC), as well as inform prevention and response to future outbreaks of Ebola Virus Disease and other similar diseases.

    Specific aims of the Call are to enhance the mobilization of interdisciplinary teams of Canadian and African health and social scientists and humanists, as well as knowledge users, to help contain the current Ebola Virus Disease outbreak in the Democratic Republic of the Congo (DRC), and prevent or mitigate the impact of future Ebola Virus Disease and similar threats to the region. Deadline to apply: July 13, 2018.
     
  • CIHR PRE-ANNOUNCEMENT: Evaluations of Interventions to Address the Opioid Crisis - Operating Grants. This funding opportunity will support the evaluation of promising health interventions and practices that have been implemented municipally, provincially and/or nationally to address the opioid crisis relevant to one or more of the four pillars of the Canadian Drugs and Substances Strategy (CDSS). To address the pressing intervention-related evidence needs of knowledge users and increase the application of knowledge in health care and/or health services policy and practice, this funding opportunity requires that at least one participant must be a Knowledge User that is involved in the intervention being evaluated. The total amount available for this funding opportunity is $ 1,500,000, enough to fund approximately 15 grants. Program Launch: June 2018; Registration date: August 2018; Deadline for full applications: September, 2018.
     
  • LG Chem Global Innovation Contest (GIC 2018). This program is a platform for research collaboration designed by LG Chem that will be initiated with novel proposals from universities and research institutions from all over the world. Please visit their website for specific keywords for GIC 2018, or visit UofT funding opportunities webpage. Nominees of this contest can earn up to $150,000 each for multi-year research activities and may also have the opportunity to collaborate with R&D teams in LG Chem to realize their proposed solutions. Deadline for submission of proposals: September 30, 2018.
     
  • Department of Defense: Congressionally Directed Medical Research Programs. Various deadlines.
  • Alex's Lemonade Stand Foundation: Familial RUNX1 Research Program. ALSF is committed to creating opportunities for new and innovative research into treatments and cures for childhood cancers. The objective of the Familial RUNX1 Research Program, presented by the Babich family Foundation, is to fund research of particular importance to families affected by familial platelet disorders (FPDs) leading to acute myeloid leukemia (AML) due to germline RUNX1 mutations with the ultimate goal of developing effective therapies to prevent the onset of AML. Upper amount: USD $250,000 over two years. Deadline for Letters of Intent: July 2, 2018

June 15, 2018
 

  • Tri-Agency Research Data Management Policy - CONSULTATION ON DRAFT. The three federal research funding agencies—CIHR, NSERC, and SSHRC, have developed a draft Tri-Agency Research Data Management Policy, which aims to support Canadian research excellence by fostering sound digital data management and data stewardship practices. The draft policy includes suggested requirements related to 1. Institutional data management strategies; 2. Researcher data management plans; and 3. Data deposit. The agencies have invited institutions, associations, organizations and individuals to comment on the draft policy and its usefulness in advancing data management practices in Canada. Feedback will inform the final design of the policy, which the agencies plan to launch in 2019.  The feedback period will run until August 31, 2018. 

    We encourage members of the University community to provide their own input directly to the email addresses on the Tri-Agency website, and to share their submission with us if possible at vpri.reports@utoronto.ca.
    It is important that there be broad input from as broad a range of disciplines as possible to reflect the unique aspects of data management in different areas of scholarship.  Given the importance of data management for the University of Toronto community, we will be submitting an institutional response to the call for feedback. Additional information can be found in the agencies' Frequently Asked Questions (FAQs)
     
  • CIHR Launches Transitions in Care Initiative. The Transitions in Care (TiC) initiative is a multi-Institute initiative that aims to improve the health and wellness of Canadians by supporting research that transforms the health system to optimize the outcomes of individuals experiencing transitions in care.
    WEBINAR: July 5, 2018 from 2pm - 3:30pm EDT. Register here.
     
  • NSERC Discovery Grant NOI: INFORMATION SESSION. In order to apply for a Discovery Grant in November 2018, an applicant MUST complete and submit an online Notice of Intent by 8 pm EST on August 1, 2018. If you do not submit a Notice of Intent by the deadline, you will NOT be eligible to apply in November for a Discovery Grant. In addition,  UofT Research Services will be holding an information session on Wednesday July 18, 2018 from 1pm to 3pm in BA 1220, Bahen Centre, 40 St George St. Please RSVP by July 13th, 2018 to Teresa.Trimboli@utoronto.ca, RFA, Research Services; 416-978-2525. Topics covered in the session include the Notice of Intent, program requirements, eligibility requirements, changes for this year’s competition (Research Portal and Canadian Common CV), evaluation criteria and proposal development. 
    For submission details please UofT Research Services webpage, as well as the NSERC Discovery Grants webpage.
  • PRE-ANNOUNCEMENT: Canadian Microbiome Initiative 2 (CMI2): A Focus on Function and Translation Research Teams. The overall goal of the CMI2 is to enable the development of effective preventative and therapeutic interventions through a deeper understanding of the role of microbiome in human health. The upcoming competition will support Research Teams to develop new knowledge on the causational roles of microbiome in human health and disease which will lead to the development of new preventative and therapeutic interventions. The total amount available for this funding opportunity is $14,350,000. This amount may increase if additional funding partners participate, enough to fund a minimum of 7 grants. Additional funding is available through Mitacs to fund internships for graduate students and post-doctoral fellows in CMI2 funded projects. Anticipated launch date: Summer 2018.

  • NSERC Idea to Innovation (I2I): Commercialization Grants. Four times per year, the NSERC accepts applications for its “Idea to Innovation” (I2I) program, for the purpose of accelerating pre-competitive technologies for transfer to a Canadian company. Successful applicants receive awards of up to $125,000 for each phase of their commercialization project, with additional funding available as the project progresses. Applicants can apply to various phases of the I2I program. For more information contact innovations.partnerships@utoronto.ca or visit NSERC`s websiteUofT Internal application deadline for current round: Friday, June 22, 2018; Sponsor deadline: July 3, 2018.

  • Explore partnering with Sanofi Pasteur: Development and production of human vaccines, both prophylactic and therapeutic, including vaccines for chronic infectious diseases. Interest list here.

  • Gilead Sciences Research Scholars Program in Cystic Fibrosis. This program supports innovative science research that will advance knowledge in the fields of pediatric and adult cystic fibrosis. The awards provide financial support to 3 junior faculty researchers in Canada, Europe, or the United States for a 2 year period. Each award is funded up to USD $130,000 over two years. Deadline for submissions: July 20, 2018.
     
  • Autism Speaks: 2018 Treatment Research Grants. Autism Speaks invites Treatment Research Grant applications to conduct innovative studies of novel treatments and interventions for people with autism spectrum disorder (ASD) throughout the life span. These may include medical approaches such as pharmacological treatments and complementary and alternative forms of health care, as well as behavioral and/or psychosocial interventions. Maximum amount: $250,000 per year for up to 3 years, with a maximum of $750,000 per award. Deadline for Letters of Intent: July 18, 2018.
     
  • National Multiple Sclerosis Society (NMSS): Collaborative MS Research Centre Awards. The following focus areas are critical to advancing breakthroughs that will identify solutions for people living with MS today and ultimately lead to prevention and a cure: Define the contribution of genetics, risk factors and their modifiers to the risk for developing MS and disease course, and develop strategies to prevent, treat and cure all forms of MS; Understand MS pathology and pathophysiology; Understand and treat MS progression; Identify strategies for neuroprotection and nervous system repair; and Elucidate the cause of MS symptoms, the impact of comorbidities, and identify rehabilitation, wellness behaviors and lifestyle approaches. Upper amount: USD $750,000 over five years. Deadline for pre-applications: August 30, 2018.
     
  • Cerebral Palsy Alliance: Career Development Grants. These are unrestricted grants to be used by the award recipient for any of the activities as listed below to assist in the recipient's career pursuits. Applicants must ensure their project addresses the Research Foundation's priorities: Aetiology, causal pathways; Prevention; Early identification, early intervention; Novel interventions, novel treatments; and Cure. Upper amount: AUD $250,000. Deadline for submissions: August 31, 2018.
     
  • Wings for Life (WLF) Spinal Cord Research Foundation. 
    • Project Research Grants:  Research projects may address all aspects of spinal cord lesions, nerve regeneration, trophic support of injured neurons and functional changes induced by lesions (preferentially in mammals). Proposals should have a view to translation from the laboratory to the clinical setting and have the potential to provide real benefits to human patients.  Clinical research projects can be situated in the fields of diagnosis, acute lesion management (including surgery), neurology, urology, rehabilitation and other areas related to paraplegia. Deadline for preliminary proposals: September 2, 2018.
    • Individual Research Grants: This grant is intended only to cover the salary of the applicant: Post-docs, PhDs, and/or technicians. The goals of the individual research grant program are to encourage new investigator's work on regeneration and recovery processes and to encourage researchers to develop new ideas and/or to transfer their efforts of other areas into spinal cord research.  Deadline for preliminary proposals: September 2, 2018.

 

June 4, 2018
 

  • Annual Faculty of Medicine Grant Writing Workshop 2018. Join us to learn more about services available through the Office of the Vice Dean, Research & Innovation; Behind the scenes of grant review panels; and Grant Writing and Development. This event is freee to faculty, staff and post-doctoral fellows. Further details here. Poster.
    Date: Tuesday, June 26, 2018 from 9am - 12pm
    Location: Medical Sciences Building, Room 3153, 1 King's College Circle
    RSVP by June 22nd: https://medicine.utoronto.ca/form/annual-faculty-medicine-grant-writing-workshop-2018
     
  • New resources for U of T Inventors and Entrepreneurs. The Innovations & Partnerships Office (IPO) is pleased to provide two new resources for faculty, researchers, and students interested in commercializing research or starting a company: The Inventor's Guide to Technology Transfer and the Start-Up Guide. These guides provide practical information on: When and how to disclose an invention; Protecting intellectual property; Navigating U of T policies and conflict of interest; Getting funding; and Bringing the technology to market. If you or your department have any questions or would like to host a workshop to learn more, contact commercialization@utoronto.ca.
     
  • CIHR: Epigenetics Clinical Translation (Funding Opportunity and Webinar). This funding opportunity is a key component of the second phase of the Canadian Epigenetics, Environment and Health Research Consortium (CEEHRC), a multi-agency, pan-Canadian initiative led by CIHR. The current funding opportunity is to support research regarding epigenetics in the clinical setting, demonstrating proof-of-concept utility of epigenetic changes in the context of diagnostics and potential therapeutic targets, in addition to building and fostering partnerships with relevant patients and stakeholders. More information about this funding opportunity is available on ResearchNet. To support applications in this area, an information webinar is being held June 13, 2018 at 1:00 p.m. (EDT). Participation in the webinar is not required to submit an application, but it is encouraged. A recording of the webinar and slides will be available upon request after the webinar for those unable to attend. Registration deadline: September 5, 2018; application deadline: October 10, 2019.
     
  • CIHR Pre-Announcement: Canadian Microbiome Initiative 2 (CMI2): A Focus on Function and Translation Research Teams. The upcoming competition will support Research Teams to develop new knowledge on the causational roles of microbiome in human health and disease which will lead to the development of new preventative and therapeutic interventions. Full details for this funding opportunity will be available on ResearchNet soon.
     
  • CIHR: Sex, Gender and Health Research (Video). Assessing Sex and Gender in Peer Review learning video is now available.
     
  • Pre-Announcement: Rapid Research Response to the DRC Ebola Outbreak. The Government of Canada, through CIHR, SSHRC and the International Development Research Centre (IDRC), is now working in partnership with the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) and other international agencies to launch a rapid research response. They intend to make available a combined $1.5 million CAD to support partnered teams of Canadian and African researchers to conduct health services research, population health research and/or social science research in the context of this particular health emergency. The full Request for Applications is expected to be posted in 2-4 weeks, after which eligible researchers will have approximately four (4) weeks to submit short applications for peer-review. Applicants will be expected to justify why their proposed research requires this rapid response funding and cannot wait for regular funding opportunities made available through CIHR, SSHRC or IDRC.
     
  • Simons Foundation: Genomic Analysis for Autism Risk Variants in SPARK. Grants awarded through this RFA are intended to advance our understanding of the genetic basis of autism. Investigators who are interested in analyzing genomic data in innovative ways from thousands of SPARK families are encouraged to apply. Available data will include whole-exome and genome-wide genotyping data from approximately 4,500 individuals with autism spectrum disorder (ASD) and their biological parents. Approximately half of these families will also have genomic data from an unaffected sibling. In addition, whole-genome sequencing data will be available from approximately 400 other ASD individuals, plus their biological parents and unaffected siblings. A limited phenotypic dataset for all participants will be available. Upper amount: $100,000 USD over 18 months. Deadline for Notice of Intent: June 22, 2018; Full proposal deadline: July 27, 2018.
     
  • Solving Kids' Cancer: Therapeutic Development Initiative (TDI) - Funding for High-Impact Pediatric Cancer Research. The TDI's goal is to support innovative clinical studies that are high on the risk/reward spectrum while, at the same time, investigating these research questions efficiently and effectively. Priority is given to proposals that introduce therapeutic agents and modalities which are first-in-children and have a strong potential to improve treatment outcomes. The TDI of SKC only supports clinical research. The organization specifically focuses on novel clinical studies for neuroblastoma, brain tumors and sarcomas. Upper amount: $600,000 USD for up to two years. Deadline for preliminary proposals: Continuous.
     
  • Vasculitis Foundation: Research Program. The VF Research Program provides one- or two-year seed grants to support pilot studies in researching: Etiology/Pathogenesis; Epidemiology, including genetics; Diagnosis, including identification of disease subtypes; and Treatment/Management, including therapeutics to treat vasculitis or prevent complications, bio markers, and psychosocial outcomes. Maximum amount: $50,000 USD over one or two years. Deadline for Letters of Intent (new): June 15, 2018.

    SPECIAL REQUEST FOR PROPOSALS:  The Vasculitis Foundation is partnering with the Swiss Foundation for Research on Muscle Diseases, Cortaillod, Switzerland, to fund research on Polymyalgia rheumatica.  To learn more about this special funding opportunity, please contact Joyce Kullman, VF Executive Director:  jakullman@vasculitisfoundation.org
     
  • Alzheimer's Drug Discovery Foundation (ADDF): Accelerating Drug Discovery for Frontotemporal DegenerationThe ADDF and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate and support innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy) drug discovery programs for FTD through this request for proposals. Funding priorities: 1) Lead optimization of novel disease-modifying compounds, including medicinal chemistry refinement and in vitro ADME. 2) Testing of novel lead compounds, biologics, or repurposed drug candidates in relevant animal models for in vivo pharmacokinetics, dose-range finding, target engagement, in vivo efficacy, and/or preliminary rodent tolerability studies. Average award amount: $100,000 - $150,000 USD. Deadline for Letters of Intent: July 13, 2018.
     
  • Histiocytosis Association: Request for Research Proposals. Proposals for scientific research are accepted for studies into the causes, mechanisms, and improved means of treatment for histiocytic disorders. Proposals are evaluated on the basis of science, feasibility, and relevance. All proposals are expected to address one or more of the histiocytic disorders. Upper amount: $50,000 USD. Deadline for proposals: July 1, 2018.
     
  • Kennedy's Disease Association. The Kennedy's Disease Association (KDA) is planning to fund one or more research grants this fall to further the understanding of the pathological mechanisms of Kennedy's Disease. Applications from junior investigators and from senior post-doctoral fellows are encouraged. Upper amount $50,000 USD. Deadline for proposals: July 30, 2018.
     
  • Global Lyme Alliance (GLA): Research Grant Award Program. GLA encourages proposals for the 2018-19 Research Grant Award Program that explore regulation of Lyme disease and other tick-borne disease pathogenesis, with an emphasis on the role of an individual's microbiome as well as genetic and epigenetic factors that might inform a "personalized medicine" approach to treatment. Proposals in other topical areas related to Lyme and other tick-borne diseases also will be accepted. Small-scale grants for proof-of-concept studies lasting one year, can be requested for between USD $50,000 and $100,000. Full-scale grants may request larger amounts, up to USD $175,000 per year to be spent over the course of a two to three-year period of funding. Deadline for proposals: August 1, 2018.
     
  • Leukemia & Lymphoma Society: Specialized Centre of Research (SCOR) Program. The objective of the SCOR grant program is to enhance the development of innovative strategies for the treatment, diagnosis, or prevention of hematological malignancies. Upper amount: $1,000,000 per year for five years. Deadline for Letters of Intent: August 31, 2018.
     
  • Leukemia & Lymphoma Society: Translational Research Program. LLS supports research, patient aid, community service programs, advocacy, and public and professional education. The formation of the Translational Research Program (TRP) was to foster collaboration between basic and clinical scientists with the intent of enhancing the transfer of basic research findings to clinical usefulness. Awards are limited to an annual maximum of $200,000 USD for years. Two additional years may be available through a competitive, peer-review renewal. Deadline for Letters of Intent: August 31, 2018.
     
  • National Organization for Rare Disorders, Inc. (NORD): Rare Disease Research Grant Program. The purpose of the NORD Rare Disease Research Grant Program is to encourage meritorious scientific and clinical studies designed to improve the diagnosis or therapy of rare "orphan" diseases. Grants will be awarded to academic researchers to initiate small scientific research studies or clinical trials. Deadline for applications: July 16, 2018.
    • Alveolar Capillary Dysplasia with Misalignment of the Pulmonary Veins (ACD/MPV)
    • Appendix Cancer and Pseudomyxoma Peritonei (PMP)
    • Familial Hypercholesterolemia 
    • Malonic Aciduria 
    • New-Onset Refractory Status Epilepticus (NORSE) and Febrile Infection-Related Epilepsy Syndrome (FIRES) 
    • PACS1-Related Syndrome (Schuurs-Hoeijmakers Syndrome)
    • Primary Orthostatic Tremor 
       
  • Jain Foundation. Research for the dysferlinopathies (LGMD2B and Miyoshi Myopathy). The Foundation funds research using a non-traditional funding model. The explicit goal of the Foundation is to expedite development of a treatment or cure for the dysferlinopathies (LGMD2B and Miyoshi Myopathy).  The project must have direct relevance to dysferlin deficiencies - either to extend the understanding of the disease or a unique approach to a treatment for the disease. The project should not have been previously performed elsewhere and sufficient due diligence should have been done to find out if the same project is currently being done in another lab. Deadline for preliminary proposals: Continuous.
     
  • MedEvac Foundation International: Grant Program. The Foundation awards funds to support the development of research and education in air medical and critical care ground transport. Grants are available to any person who is qualified to conduct research in the critical care transport industry for the proposed funding year. Visit their website for the Foundation's priorities for their 2018 grant cycle. Deadline for applications: August 3, 2018. 
     

 

May 24, 2018
 

  • NSERC Discovery Grant NOI webinars. NSERC has announced a number of webinars for the 2018 competition for NSERC Discovery Grant. The webinars will highlight how to submit a NOI using the Research Portal and the NSERC Canadian Common CV (CCV)
    ENGLISH: June 19 and July 12 from 1pm-3pm ET
    FRENCH: June 21 and July 10 from 1pm-3pm ET 

    Conference # 1 877-413-4790; Conference ID: 7462843; Link: https://nsercofcanada.adobeconnect.com/_a1139318731/complete-application/ 

    In order to be better prepared for these webinars, NSERC invites you to familiarize yourself with the following documents:
  • Council of the Great Lakes Region Presentation and Discussion. The Council of the Great Lakes Region (CGLR) seeks to engage with U of T researchers. Mark Fisher, President and CEO of the CGLR, will be conducting an information session at U of T to present and discuss the Council’s work. This session is open to any faculty member from any department who is interested in finding out more about the CGLR and about potential involvement in the Council's research projects and events. Launched in 2013, the CGLR brings all levels of government in the Great Lakes Region together with industry, academia, and the broader non-profit sector in order to create a stronger and more dynamic culture of collaboration across the border and key sectors. Its main activities include conducting public policy research, convening dialogues, and advocacy, with a focus on fully harnessing the region's economic strengths and assets, improving the well-being and prosperity of its citizens, and protecting the environment for future generations. 
    Date: June 19, 2018, 10am - 11am
    Location:
    Simcoe Hall, 27 King's College Circle, President's Boardroom, room 132
    Video and teleconferencing arrangements will be made for those who require it.
    If you would like to attend, please RSVP to events.vpresearch@utoronto.ca.
    For more information on the CGLR
     
  • Banting Research Foundation - Executive Director Position. The Banting Research Foundation is seeking a part-time Executive Director to manage all activities of the Foundation, including its annual grant program. The position reports to the Board of Trustees, and executes all policies and decisions of the Board. A science background and business administration experience, preferably in the not-for-profit/charity realm, are important. Knowledge of fundraising procedures is an asset. This role is broad in scope and suits someone comfortable with working independently with minimal day-to-day direction. Please see the position description for details of the role.
    Contact: info@bantingresearchfoundation.ca
     
  • The Terry Fox Research Institute (Terry Fox Foundation): 2019 Research Programs.
    • The Terry Fox New Frontiers Program Project Grants support multidisciplinary teams of excellence that contribute to well-defined research topics of relevance to cancer. Deadline for Letters of Intent: July 13, 2018.
    • The Terry Fox New Investigator Awards support outstanding young researchers as they develop their careers as independent research scientists or clinician scientists to undertake high-quality cancer research while in close collaboration with established TFRI-funded research teams. Deadline for applications: July 30, 2018.
       
  • Neuroendocrine Tumor Research Foundation (NETRF). NETRF Grant Funding Opportunities. NETRF is seeking investigators and teams of investigators from around the world, with the tools to study neuroendocrine cancers in new ways. The foundation is very interested in grant proposals from multidisciplinary groups comprised of basic scientists, clinicians, and experts in bioinformatics, bio-nanotechnology, or other relevant disciplines. Proposals that cover promising and potentially transferable mechanisms and/or technologies, which have been applied successfully to other areas of cancer research, are highly desirable, and will be evaluated based on their level of applicability to NETs. While NETRF will continue to fund research in pancreatic and gastrointestinal NETs, this year it also invites grants that propose to study typical or atypical lung carcinoids. The deadline for Letters of Intent is June 15, 2018.
    • Accelerator Award: 4-year grant in the amount of $1,200,000 USD ($300K per year)
    • Petersen Investigator Award: 2-year grant in the amount of $300,000 USD ($150K per year)
    • Pilot Project Award: 1-year grant at either $50K or $100K USD/year
       
  • American Association for Cancer Research (AACR): Stand Up to Cancer T-Cell Lymphoma Dream Team Translational Research Grant. This research grant will fund a translational cancer research project focused on T-cell lymphoma that will address critical problems in patient care, including prevention strategies for those at risk, and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, collaborative Dream Team of expert investigators. Projects must be designed to accelerate the application of new preventive, diagnostic or therapeutic approaches to the clinic (i.e., lead to patient involvement within 2-3 years from the beginning of the grant). To maximize creativity, innovation, and collaboration, the Dream Team must include laboratory and clinical researchers, senior and/or young investigators, and senior scientists who have not worked together in the past. Amount $8,000,000 USD over 3 years. Deadline for Letters of Intent: July 2, 2018.
     
  • Saving Tiny Hearts Society: Research Grants. The Society awards research grants to early stage science with unique hypotheses fostering the next generation of congenital heart defect research creating a strong foundation of preliminary evidence to make scientific advancements. Priority will be given to well-designed hypothesis driven research that will impact the lives of children and adults living with congenital heart disease. Amount: Up to $75,000 USD for a single year grant. Deadline for applications: July 16, 2018.
     
  • A-T Children's Project: Investigator Initiated Grants. The A-T Children's Project provides competitive grant awards for basic and translational research grants related to A-T. Applicants please note that unless specific Requests for Applications are present, the A-T Children's Project is currently focusing its funding efforts on proposals that apply innovative and novel strategies for suggesting, developing and evaluating specific disease-modifying and symptomatic interventions with an emphasis on: pre-clinical research and clinical studies. As such, these types of applications will be given priority funding. One- and two-year projects are funded up to a maximum total direct cost of US$75,000 per year. Budgets for up to US$150,000 for a two-year project are acceptable. Deadline for Letters of Intent: August 1, 2018.
     
  • JDRF: Strategic Research Agreements. Available funding for the Strategic Research Agreements will be reviewed on a per-application basis. The deadline for Concept Paper/Proposal for each program is August 1, 2018 or November 1, 2018.
    • Strategic Research Agreements - Clinical SRA Projects are intended to support research programs that qualify under the JDRF clinical review process. This funding mechanism is intended to support early-stage clinical trials to test therapeutic approaches as well as non-interventional patient oriented studies that are intended to lead to the development of clinical interventions and monitoring tools (such as markers) for diabetes and its complications. 
    • Strategic Research Agreements - Multi-Project SRA provides a mechanism to stimulate new collaborations between clinical and basic scientists and/or between scientists from diverse backgrounds as a means to conceive and develop new approaches to major challenges, potential breakthroughs, or persistent obstacles to progress along the various paths to prevent, treat or cure Type 1 diabetes and its complications.
    • Strategic Research Agreements - Single Project. JDRF's Strategic Research Agreements were created to provide research funding for single or multiple investigators to address critical gaps and challenges and potential breakthroughs in Type 1 diabetes research. The Strategic Research Agreement is a partnership between Investigator(s) and JDRF Scientists to help address roadblocks and accelerate JDRF's mission through support of cutting-edge scientific investigation.
       
  • NIH: Various Opportunities. Unless otherwise stated in the funding opportunity, see Standard Due Dates Schedule for deadlines for each Grant category. If you intend to apply via the University of Toronto, it is recommended you contact Krista Montgomery in Research Services at least two weeks prior to submitting an NOI or application.  For more information on NIH application and the submission process, please visit the University's Research Funding Opportunities found here.
    • Targeted In Vivo Delivery of Gene Therapeutics for HIV Cure (R01)
    • Novel Nucleic Acid Sequencing Technology Development (R01) and (R21)
    • BRAIN Initiative: Targeted BRAIN Circuits Projects- TargetedBCP (R01)
    • In Vivo Synaptic Function in Alzheimers Disease and Related Dementias (R21)
    • Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33)
    • Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33)
    • Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate Neurotherapeutic Discovery (R61/R33)
    • Harnessing Big Data to Halt HIV (R01)
    • Identification and Management of Behavioral Symptoms and Mental Health Conditions in Individuals with Intellectual Disabilities (R01)
    • BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01)
    • Investigation of the Transmission of Kaposi Sarcoma-associated Herpesvirus (KSHV)(R01) and (R21)
    • Understanding Skeletal Effects of Type 1 Diabetes (R01)
    • International Research Collaboration on Drug Abuse and Addiction Research (R01)
    • Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34)
    • Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34)
    • Maternal Nutrition and Pre-pregnancy Obesity: Effects on Mothers, Infants and Children (R01)
    • Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34)
    • Novel Genomic Technology Development (R01) and (R21)
    • Cardiothoracic Surgical Trials Network (CTSN) Linked Clinical Research Centers (UM1)
    • Precision Imaging of Oral Lesions (R01) and (R21)
    • Genetic analysis of non-human animal models to understand the genomic architecture of substance use disorders and addictive behaviors (U01)

 

May 14, 2018
 

  • UPDATE - CIHR launches new Equity and Diversity Questionnaire for applicants. As Canada's health research investment agency, CIHR manages over 100 funding competitions each year. As outlined in the CIHR Equity Strategy, we are committed to ensuring that all of our programs and peer review processes result in the fair and impartial treatment of all participants. To fulfill this commitment, CIHR must collect data on a number of equity dimensions to allow us to identify and address potential inequities. As of May 15, 2018, application participants for all CIHR programs must complete an Equity and Diversity Questionnaire. Read more.
     
  • CIHR: RFA - Understanding the Health Impact of Inactivity. This funding opportunity is the first component to be launched under the much larger CIHR Transitions in Care initiative. This Funding Opportunity will support ambitious, innovative, multi-disciplinary collaborative research projects to help understand the health impacts of inactivity. The ultimate goal is to eventually develop solutions for improving the quality of life of older adults, inform transitions in care, and mitigate health risks associated with life in space. The total amount available for this funding opportunity is $1,600,000, enough to fund approximately 8 grants. The maximum amount per grant is $200,000 for up to 18 months. Registration deadline: July 24, 2018; Application deadline: August 8, 2018.
     
  • The Weston Brain Institute: (If you have any questions about any of the below programs, please contact us)
  • Canadian Blood Services: Blood Efficiency Accelerator Award Program. The objective of this program is to improve the efficient and appropriate utilization of blood products, while maintaining the safety of the blood system. To achieve this objective, the Program will support innovative research projects that seek new knowledge or accelerate the application of existing knowledge. All project teams require at least one Canadian Blood Services employee. All project team members must have a defined role in the project, and their expertise must be clearly required to adequately address project goals. Applicants are encouraged to contact centreforinnovation@blood.ca if help is needed to identify a Canadian Blood Services project team member. They anticipate funding two (2) projects annually at a maximum value of $30,000 per project. Deadline for applications: July 15, 2018. 
     
  • Mitacs Elevate - Spring 2018 Call for Proposals. Mitacs Elevate is a postdoctoral fellowship with a customized research management training component. Elevate fellows progress through the program in a cohort, giving them cross-disciplinary networking and peer-learning opportunities they might not have otherwise in their careers. Over the two-year fellowship, Elevate fellows divide their time between their partner organization project and university-based research with their faculty supervisor. UofT internal deadline: July 4, 2018; Sponsor deadline: July 11, 2018.
     
  • Simons Foundation Autism Research Initiative (SFARI): Explorer Awards. Explorer Awards are intended to provide resources to support exploratory experiments that will strengthen hypotheses and lead to the formulation of competitive applications for subsequent larger-scale funding by SFARI or other organizations. Innovative, high-risk/high-impact proposals are prioritized. They especially encourage applications from investigators who are new to the field of autism, but who have expertise that could be brought to bear on this complex disorder. Award amount: $80,000 for one year. ** Note: The Explorer Award program is ending soon (the last receipt of applications will be June 15, 2018).
     
  • amfAR: Mathilde Krim Fellowships in Basic Biomedical Research. The goal of this program is to facilitate the exceptional postdoctoral researcher’s transition to an independent career in HIV/AIDS research within an academic or non-profit institution. maximum funding is $150,000 USD for two years. Register for Portal Log-in Forms (required) by June 7, 2018 at 3pm EDT; Deadline for Letter of Intent: June 11, 2018 at 3pm EDT.
     
  • Lung Cancer Research Foundation (LCRF): Research Grants. The LCRF grant program provides funding for innovative research focused on the prevention, diagnosis, treatment and cure of lung cancer. The goal of the grant program is to fund innovative projects across the spectrum of basic, translational, and clinical research. The Foundation encourages applications for projects investigating a wide variety of research topics. Applicants from US-based and international institutions are eligible to apply. Amount: Up to $150,000 USD over two years. Deadline for applications: July 2, 2018.
     
  • Meso Foundation: Grants for Mesothelioma Research. The Mesothelioma Applied Research Foundation (Meso Foundation) is calling for applications for available mesothelioma research funding. They are an international collaboration of patients and families, physicians, advocates, and researchers dedicated to eradicating the life-ending and vicious effects of mesothelioma. Eligible projects may relate to benchwork, translational or clinical research that is not presently funded and may be conducted through any not-for-profit academic, medical or research institution. Amount: Up to $100,000 USD over two years. Deadline for Letters of Intent: July 1, 2018.
     
  • International Fibrodysplasia Ossificans Progressiva Association (IFOPA): ACT (Accelerating Cures and Treatments) for FOP Grant Program. The IFOPA offers the ACT  for FOP grant program to help enable the development of safe and transformative therapies for FOP. The research grant program provides, through a competitive application process, funding to scientists conducting research on fibrodysplasia ossificans progressiva (FOP). Research grants should focus on the discovery and advancement of therapeutic approaches to FOP. FOP researchers with a doctoral degree (MD, PhD or equivalent) at any stage of their career in any country are eligible to apply. Upper amount: $100,000 USD. Deadline for proposals: July 6, 2018.
     
  • Pulmonary Hypertension Association (PHA): PHA/ATS Research Fellowship in Pulmonary Arterial Hypertension. The award will support novel studies of the diagnosis, pathogenesis, treatment or outcomes of pulmonary hypertension. A primary goal of this research program is to enable new faculty-level investigators to make the transition to established investigators. Partnerships between junior and senior investigators are strongly encouraged, particularly for new investigators who are within 1 to 5 years of the completion of their training. Both U.S. and non-U.S. based investigators are encouraged to apply. One of the investigators must be an ATS member at the time of application, and the Principal Investigator must be an ATS member at the time that the grant is awarded. Amount: Up to $80,000 USD over two years. Deadline for Letters of Intent: June 12, 2018.
     
  • International Myeloma Foundation (IMF): Brian D. Novis Senior & Junior Research Awards. These awards go to researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undetermined significance) as well as immunoglobulin derived amyloidosis. This year's awards will be $50,000 each for the junior grant and $80,000 for the senior grant. Deadline for applications: August 1, 2018.
     
  • Department of Defense: Congressionally Directed Medical Research Programs. Various deadlines.
    • Amyotrophic Lateral Sclerosis 
    • Bone Morrow Failure 
    • Gulf War Illness 
    • Lung Cancer 
    • Multiple Sclerosis 
    • Ovarian Cancer 
    • Peer Reviewed Cancer 
    • Peer Reviewed Medical 
    • Tick-borne Disease

 

May 3, 2018
 

  • CIHR/NSERC/SSHRC Collaborative Health Research Projects (CHRP): INFORMATION SESSION. The University is hosting an information session in anticipation of the 2018 CHRP funding opportunity offered by CIHR in partnership with NSERC and in collaboration with SSHRC. The CHRP program supports innovative, interdisciplinary, collaborative research projects, requiring participation from the natural sciences or engineering community together with the health sciences community. CHRP projects require the translation of the research results to knowledge/technology users (KTUs) and related stakeholders outside the academic or training environment. As such, the proposed research projects must have a strong focus on knowledge translation (KT) and lead to health and economic benefits for Canadians, more effective health services and products, and/or a strengthened health care system. 

    At this information session Research Services will provide an overview of the CHRP program and the application process including any internal U of T requirements.  In addition, Professor Craig Simmons, Distinguished Professor of Mechanobiology, and a multiple CHRP grantholder, will provide insight on the program from the researcher’s perspective as well as helpful tips learned from serving on the CHRP peer review committee.
    Date: Thursday May 10th from 11am -12pm. 
    Location: Medical Sciences Building, Room 2172, 1 King's College Circle
    Please register by Monday, May 7th to mark.bold@utoronto.ca 

    *Please note* There is also sponsor-based webinar session which is now open for registration for Monday, May 7, 2018, from 1:30 p.m. to 2:30 p.m. EDT. 

     
  • NSERC Discovery Grant: INFORMATION SESSION. Uof T invites you to particpate in an in an NSERC Discovery Grant information session, with presentation by Lise Désabrais, a Program Officer with NSERC.
    The session will cover: focuses on the preparation of a Discovery Grant application, program requirements, eligibility, an overview of the results from the recent competition and any key NSERC updates. This session will also include guest speaker (former or current Discovery Grant committee member) that will outline details in the application and evaluation process.
    Date: May 30th from 1:30pm - 3:30pm.
    Location: Sanford Fleming Building, Room 1105, 10 King's College Circle
    Please RSVP by May 20th to Teresa.Trimboli@utoronto.ca 
     
  • CIHR Team Grant: ME/CFS (Myalgic Encephalomyelitis / Chronic Fatigue Syndrome) Collaborative Project. The objective of this grant is to create an environment where Canadian researchers collaborating with NIH’s CRCs and DMCC can combine their relative strengths to advance our understanding of ME/CFS, and to define the cause(s) of and discover improved treatments for ME/CFS. The total amount available from CIHR for this funding opportunity is $1,775,000, enough to fund one (1) team. Application deadline: June 6, 2018.
     
  • PRE-ANNOUNCEMENT: CIHR Epigenetics Clinical Translation Funding Opportunity. CIHR will soon launch an Epigenetics Clinical Translation funding opportunity aimed at advancing epigenetic discoveries into the translational realm.  The specific objectives of this funding opportunity are to:
    •    Evaluate applications of epigenetics in the clinical setting, including through clinical trials, demonstrating proof-of-concept utility of epigenetic changes as biomarkers, diagnostics and targets for potential therapeutics;
    •    Support and build upon existing Canadian research expertise in epigenetics for clinical translation outcomes;
    •    Build capacity for epigenetics clinical research through training and mentoring;
    •    Foster partnerships between various knowledge user sectors and stakeholders 
    Please note that there will be a requirement for applicants to secure cash and/or in-kind funding to supplement the CIHR grant. More information about this funding opportunity will be available on ResearchNet once launched.
    Anticipated launch date: May 2018; Anticipated registration date: September 2018.
     
  • PRE-ANNOUNCEMENT: CIHR Team Grant - Human Immunology Research TeamsThe Human Immunology Initiative involves the development of standardized procedures and their application to research on autoimmune diseases. It is divided into two distinct funding opportunities: 1) The Standardization Core; and 2) Human Immunology Research Teams. This funding opportunity will support projects in human immunology, in the field of autoimmune diseases, relevant to the following research areas:
    •    normal immune function and dysfunction in relation to autoimmune diseases, including sex-related mechanisms and differences in prevalence and disease severity among at-risk populations; and
    •    novel therapeutic strategies for autoimmune diseases, including new targets, efficacy and potential toxicity. Total amount available for this funding opportunity is $4,920,000. Developmental grants of up to $20K may be offered at the LOI stage. Maximum amount per award is $400K per yer for up to four years.
     
  • Prostate Cancer Canada: Movember Translation Acceleration Grant (TAG) to Validate Predictive Markers for Treatment Response and Outcome. This request for applications (RFA) solicits proposals from groups developing and validating methods to specifically and accurately predict treatment response and/or patient outcome using an appropriate assay. The end goal is clinical validation of the approach and more accurate and personalized selection of treatments for patients with prostate cancer. It is expected that a multidisciplinary approach will be required and each Movember TAG application may consist of independent investigators based in multiple institutions. PCC also strongly encourages, wherever possible, that applications would access and use existing banked clinical specimens. PCC will only consider projects that are completely focused on prostate cancer. Award amount: Up to $1.5M over 3 years. Registration deadline: May 15, 2018; Full application deadline: July 9, 2018.
     
  • Quebec Consortium for Drug Discovery (CQDM): Quantum Leap. The Quantum Leap program is intended to support outstanding translational research projects implementing state-of-the art technologies with very high potential impact in key areas of unmet needs within the biopharmaceutical industry. It is expected that the funded technologies should provide valuable opportunities for future collaborations and/or investment from key partners on a global scale. This program is aimed at developing highly innovative technologies, platforms or tools with strong preliminary data showcasing high potential to drastically improve, facilitate and accelerate the process of discovery and development of drugs that prevent, treat or cure diseases in all major indications pursued by the biopharmaceutical industry. The research agenda extends to all scientific and technical fields related to biopharmaceutical R&D and all disciplines that could provide new cutting-edge platforms to enhance and improve biopharmaceutical research productivity. The expectations are that the translational research projects will generate tangible results with catalytic effects on developing optimized approaches to the treatment of diseases by the biopharmaceutical industry. Award amount: $500K - $2M, minimum 1 year, maximum 3 years. Application deadline: June 1, 2018. 
     
  • Bill and Melinda Gates Foundation: Ending the Pandemic Threat - A grand challenge for universal influenza vaccine development. The goal of this Grand Challenge is to identify novel, transformative concepts that will lead to development of universal influenza vaccines offering protection from morbidity and mortality caused by all subtypes of circulating and emerging (drifted and shifted) Influenza A subtype viruses and Influenza B lineage viruses for at least three to five years. It is envisaged that such a universal influenza vaccine would address the threat from both seasonal and pandemic influenza, thus alleviating the need for annual seasonal influenza vaccination campaigns, averting significant global morbidity and mortality, and better preparing the world for the next influenza pandemic. Pilot award amount USD $250K up to $ 2M over 2 years, with the anticipation that one or more pilot projects may be invited to apply for a full award up to USD $10 million. Deadline for Letter of Inquiry: June 22, 2018.
     
  • NBIA Disorders Association: Research Grants for Neurodegeneration with Brain Iron Accumulation (NBIA). The NBIA are looking for clinical and translational research studies related to the early… more » detection, diagnosis or treatment of people with Beta-propeller Protein-Associated Neurodegeneration (BPAN), caused by mutations in the gene WDR45, located on the X chromosome. The organization is interested in projects that have the potential to generate essential resources for the scientific community, advance knowledge about NBIA disease processes and produce preliminary data so that additional national and international funding can carry the work forward. Category 1 grants are up to $45K USD for one year; Category 2 grants are up to $75K USD each year for two years, with an option for a third year. Deadline for applications: June 15, 2018.
     
  • International Organization for the Study of Inflammatory Bowel Disease (IOIBD): Operating Grants. The mission of the IOIBD is to promote the health of people with IBD worldwide by setting the direction for patient care, education and research. Applicants must have an active or senior IOIBD member as PI or co-investigator. Grants to a maximum of €200,000 for up to one year may be awarded; preferably two Clinical and two Basic Science Projects. Preference will be given to grants less than or equal to €50,000. Deadline for applications: June 30, 2018.

 

April 19, 2018
 

  • U of T - University of Manchester joint workshop on collaborative opportunities in biomaterials and regenerative medicine. The University is pleased to invite those interested to participate in an exploratory workshop on potential areas of collaboration in biomaterials and regenerative medicine with the University of Manchester. The session will be led by Professor Chris Yip, Institute of Biomaterials & Biomedical Engineering & Associate Vice-President, International Partnerships at U of T and Professor Sarah Cartmell, Lead, School of Materials from University of Manchester. The launch of a collaborative fund for joint projects between University of Manchester and U of T will be announced on the morning of April 24th and will conclude the formal component of this workshop. Complete agenda and RSVP information can be found here.
    Date: April 23 & 24, 9am - 5pm. 
    Location: Wallberg Building, Room 215 (St. George Campus)
     
  • Genome Canada: Genomic Applications Partnerships Program (GAPP) Round 12The GAPP funds public-private research collaborations focused on developing genomics-derived technologies that address opportunities and challenges identified by industry, government, not-for-profits or other "receptors" of genomics knowledge and tools. Please note that the GAPP is a rolling program, and is currently in Round 12. Applicants interested in applying to the GAPP Round 12 are encouraged to contact Shobha Ramsubir at Ontario Genomics. Key Paremeters of the Program: Maximum project size: $300K - $6M (total); Co-funding: 1/3 investment from Genome Canada (max), 1/3 investment from Receptor (min) and 1/3 of other applicant-identified co-funding; Project Stage: downstream R&D/validation/pilot; Project Term: 1-3 years. Draft EOIs are due to RSO and Ontario Genomics on May 2, 2018.
    To learn more please visit the GAPP homepage, or the UofT funding opportunity.

     
  • NSERC Strategic Partnership Grants for Projects - NSERC Webinars for full applications. NSERC will host webinar sessions regarding the 2018 competition for Strategic Partnership Grants for Projects. The webinar will discuss the preparation of a Full Application. Full Applications may be submitted by applicants invited forwards by NSERC from the Letter of Intent stage. 
    English: Wednesday, April 25 at 12:30 pm ET, and Tuesday, May 1 at 12:30pm ET.
     
  • Canadian Cancer Society and the Chordoma Foundation: Chordoma Research Grants.  As a result of a fundraising partnership with the Chordoma Foundation and generous donors, there is funding available to support up to 2 meritorious applications that will impact our understanding of chordoma and generate new ideas leading to critically needed systemic therapies. It is hoped that this grant award will utilize innovative technologies and foster new collaborations in order to drive translational research findings rapidly to the clinic. Applications that build new collaborations and capacity in chordoma research are encouraged. Grant budgets may be up to $100,000 per year and a maximum of $150,000 per grant over a 2-year period, and will be non-renewable. Deadline for abstract registrations: May 1, 2018.
     
  • Alex's Lemonade Stand Foundation for Childhood Cancer: Grants and Awards. 
    • Reach Grants are designed to move hypothesis-driven research into the clinic. The $250,000, two year grant is intended to fund developmental therapeutic studies in the late stage of preclinical testing. A successful application will identify an unmet clinical need relevant to the care of pediatric patients with cancer and describe how the work performed will allow for the translation to the clinic within two years of completion. A plan and timeline for clinical testing and trial implementation is expected. This grant does not fund clinical trial expenses. Deadline for applications: May 21, 2018.
    • The ‘A’ Award is a four-year grant designed for the early independent career scientist who wants to establish a career in pediatric oncology research. The ideal applicant has an original project that is not currently being funded. Demonstration of a future commitment to pediatric cancer investigation as well as institutional support for the career development of the investigator are critical components of a successful application. The award amount is now a maximum of $200,000 per year with the possibility of additional funding in a 5th year. Deadline for applications: May 21, 2018.
       
  • National Multiple Sclerosis Society: Pilot Research Grants. The Society funds high-risk pilot grants to quickly test novel ideas. Funding is provided for one year to test innovative, cutting-edge ideas or untested methods, and to gather sufficient preliminary data to apply for longer-term funding. We welcome applications for studies related to multiple sclerosis that may serve to advance our mission of stopping MS progression, restoring function and improving quality of life, and preventing MS. The Society supports fundamental as well as applied studies, non-clinical or clinical in nature, including projects in patient management, care and rehabilitation. The maximum amount is $50,000 for one year. Deadline for pre-applications is May 7, 2018, and full applications are due on May 9, 2018.
     
  • The Champ Foundation: Call for Proposals for Pearson Syndrome. The Champ Foundation supports research toward better treatment and a cure for diseases caused by mitochondrial DNA deletions, namely Pearson Syndrome. They are releasing a call for proposals to find and fund the most innovative research projects aligned with this mission. Deadline for proposals: May 25, 2018.
     
  • The Hope Foundation: SWOG Early Exploration and Development (SEED) Fund. SWOG's mission is to improve the practice of cancer medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors, primarily through design and conduct of clinical trials. Awards are made from The Hope Foundation SEED Fund to encourage preliminary research that will potentially translate to future clinical trials or trial-associated projects (translational medicine studies) within SWOG and the NCTN. These awards may assist investigators with projects that support the following types of studies: pre-clinical data, secondary data analysis from clinical trials, pilot and feasibility studies (including early stage clinical trials), small, self-contained research projects, or development of research methodology/technology. Amount: $50,000 USD over 1 or 2 years. Deadline for applications: July 1, 2018.
     
  • NIH: Various Opportunities. Unless otherwise stated in the funding opportunity, see Standard Due Dates Schedule for deadlines for each Grant category. If you intend to apply via the University of Toronto, it is recommended you contact Krista Montgomery in Research Services at least two weeks prior to submitting an NOI or application.  For more information on NIH application and the submission process, please visit the University's Research Funding Opportunities found here.
    • Accelerating Basic and Translational Research in Hidradenitis Suppurativa (R21) and (R01)
    • Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R01) and (R21)
    • Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R21) and (R01)
    • Research on the Health of Transgender and Gender Nonconforming Populations (R21) and (R01)
    • Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low and Middle- Income Countries (R21)
    • Small Research Grants for Analyses of Data for the Gabriella Miller Kids First Data Resource (R03)
    • Impact of Initial Influenza Exposure on Immunity in Infants (U01)
    • Mechanisms Underlying the Contribution of Type 1 Diabetes Disease-associated Variants (R01)
    • Cutting Edge Informatics Tools for Illuminating the Druggable Genome (U01)
    • Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R01) and (R21)
    • Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21)
    • Investigator-Initiated Genomic Medicine Research (R01) and (R21)
    • Exploring Epigenomic or Non-Coding RNA Regulation in the Development, Maintenance, or Treatment of Chronic Pain (R61/R33)
    • Pilot and Feasibility Clinical Research Grants in Urologic Disorders (R21)
    • Pilot and Feasibility Clinical Research Grants in Kidney Diseases (R21)
    • Next-Generation Biologics for Sustained HIV Remission (R01)
    • Development of a virtual bioequivalence trial simulation platform that integrates population pharmacokinetic modeling algorithms into physiologically-based pharmacokinetic models (U01)
    • Novel Biomarkers for the Development of HIV Incidence Assays with Improved Specificity (R01) and (R21)

 

Back to Top